ROIVANT SCIENCES LTD. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
ROIVANT SCIENCES LTD. (ROIV) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $4.92 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $4.92B.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $5.29B.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $4.97B.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $4.81B.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | $4.92B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $5.29B 10-Q · filed 2026-08-06 |
| 2025-12-31 | $4.97B 10-Q · filed 2026-02-06 |
| 2025-09-30 | $4.81B 10-Q · filed 2026-02-06 |
| 2025-06-30 | $4.82B 10-Q · filed 2026-08-06 |
| 2025-03-31 | $5.19B 10-Q · filed 2026-08-06 |
| 2024-12-31 | $5.54B 10-Q · filed 2026-02-06 |
| 2024-09-30 | $5.58B 10-Q · filed 2026-02-06 |
| 2024-06-30 | $5.90B 10-Q · filed 2026-02-06 |
| 2024-03-31 | $6.45B 10-K · filed 2026-05-20 |
| 2023-12-31 | $6.58B 10-Q · filed 2025-02-10 |
| 2023-09-30 | $1.33B 10-Q · filed 2025-02-10 |
| 2023-06-30 | $1.33B 10-Q · filed 2025-02-10 |
| 2023-03-31 | $1.61B 10-K · filed 2026-05-20 |
| 2022-12-31 | $1.43B 10-Q · filed 2024-02-13 |
| 2022-09-30 | $1.51B 10-Q · filed 2024-02-13 |
| 2022-06-30 | $1.76B 10-Q · filed 2024-02-13 |
| 2022-03-31 | $2.04B 10-K · filed 2025-05-29 |
| 2021-12-31 | $2.25B 10-Q · filed 2023-02-13 |
| 2021-09-30 | $2.43B 10-Q · filed 2023-02-13 |
| 2021-06-30 | $1.96B 10-Q · filed 2023-02-13 |
| 2021-03-31 | $2.04B 10-K · filed 2023-06-28 |
| 2020-12-31 | $2.17B 10-Q · filed 2022-02-14 |
| 2020-09-30 | $2.41B 10-Q · filed 2022-02-14 |
| 2020-06-30 | $2.27B 10-Q · filed 2022-02-14 |
| 2020-03-31 | $2.09B 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |